

# Medical Research Council Sixth Small Cell Study: A Controlled Clinical Trial of Two Policies of Chemotherapy for Poor Prognosis Patients with Small-Cell Lung Cancer (SCLC)

<b>Submission date</b> 19/08/2002	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 19/08/2002	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 15/11/2019	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr - -

**Contact details**  
UKCCCR Register Co-ordinator  
MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

## Study information

### Scientific Title

Medical Research Council Sixth Small Cell Study: A Controlled Clinical Trial of Two Policies of Chemotherapy for Poor Prognosis Patients with Small-Cell Lung Cancer (SCLC)

### Study objectives

(Added 05/08/09) What is the comparison in poor prognosis patients with SCLC with the standard chemotherapy used in 3 previous MRC studies, etoposide, cyclophosphamide, methotrexate and vincristine (ECMV) and 3 courses of etoposide & vincristine (EV), with respect to palliation of symptoms, performance status, toxicity, response to treatment and survival?

As of 05/08/09 this record has been extensively updated. All updates can be found under the relevant field with the above update date. Please also note that the trial start and end dates have been changed from 19/08/2002 and 19/08/2003 respectively, as these dates were automatically generated by the system at time of registration.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

No ethics information required at time of registration.

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

### Study type(s)

Treatment

### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

### Health condition(s) or problem(s) studied

Lung (small cell) cancer

### Interventions

1. ECMV Regimen: Three courses three weeks apart of Etoposide, Cyclophosphamide, Methotrexate and Vincristine.

2. EV Regimen: Three courses three weeks apart of Etoposide and Vincristine. Thoracic radiotherapy and prophylactic cranial irradiation should not be given as a routine. If a patient needs radiotherapy to metastatic sites or to the primary site to control symptoms, the details should be decided by the radiotherapist and recorded as appropriate.

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Etoposide, cytophosphamide, methotrexate, vincristine

**Primary outcome measure**

Added 05/08/09:

1. Palliation of symptoms
2. Toxicity
3. Performance status
4. Quality of life
5. Response rate

Initial outcome measures not provided at time of registration

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

01/04/1997

**Completion date**

31/03/1999

## Eligibility

**Key inclusion criteria**

1. Primarily untreated microscopically confirmed SCLC
2. Age <80
3. Limited disease: poor performance status (World Health Organisation [WHO] grade 3 or 4). Extensive disease: performance status any grade
4. Renal function normal
5. Plasma Billirubin not greater than twice normal levels

**Participant type(s)**

Patient

**Age group**

Not Specified

**Sex**

Not Specified

**Target number of participants**

Not provided at time of registration

**Key exclusion criteria**

1. Previous anticancer treatment for current SCLC
2. Presence of other malignant disease (except previous basal cell carcinoma or in situ carcinoma of the cervix)
3. Presence of other serious condition contraindicating the study regimens

**Date of first enrolment**

01/04/1997

**Date of final enrolment**

31/03/1999

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**UKCCCR Register Co-ordinator**

London

United Kingdom

NW1 2DA

## **Sponsor information**

**Organisation**

Medical Research Council (MRC) (UK)

**Sponsor details**

20 Park Crescent

London

United Kingdom

W1B 1AL

+44 (0)20 7636 5422

clinical.trial@headoffice.mrc.ac.uk

**Sponsor type**

Research council

**Website**

<http://www.mrc.ac.uk>

## Funder(s)

**Funder type**

Research council

**Funder Name**

Medical Research Council (MRC) (UK)

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/02/1996	15/11/2019	Yes	No